PharmGen Science, Inc. (KRX:004720)

PharmGen Science Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	13,549	37,916	36,906	19,355	33,656	25,917
Short-Term Investments	532.57	532.57	531.85	531.28	531.09	4,531
Cash & Short-Term Investments	14,082	38,449	37,437	19,886	34,187	30,448
Cash Growth	-61.33%	2.70%	88.26%	-41.83%	12.28%	91.20%
Accounts Receivable	40,687	39,299	35,617	28,037	19,857	21,404
Receivables	40,687	39,299	35,617	28,037	19,857	21,404
Inventory	33,865	31,845	20,713	20,900	15,225	16,420
Other Current Assets	1,513	1,115	1,560	1,717	8,110	6,629
Total Current Assets	90,147	110,709	95,327	70,541	77,379	74,901
Property, Plant & Equipment	38,264	38,863	41,273	42,444	34,902	17,214
Long-Term Investments	193,968	195,914	188,094	187,260	92,213	37,707
Other Intangible Assets	464.32	428.06	446.37	482.27	407.73	354.16
Long-Term Deferred Tax Assets	-	-	-	-	-	3,250
Long-Term Deferred Charges	6,540	6,705	5,971	5,695	4,026	1,582
Other Long-Term Assets	10,811	10,832	10,896	10,969	11,396	534.8
Total Assets	340,194	363,450	342,008	317,391	220,324	135,544
Accounts Payable	5,438	6,621	4,868	4,938	4,505	4,480
Accrued Expenses	5,850	6,831	6,187	6,086	3,539	2,694
Short-Term Debt	18,800	38,235	37,020	38,555	46,157	19,818
Current Portion of Long-Term Debt	-	-	-	-	779.35	-
Current Portion of Leases	340.27	404.18	410.86	445.97	494.83	569.42
Current Income Taxes Payable	1,288	1,497	907.6	919	-	543.32
Other Current Liabilities	11,652	11,833	13,778	17,241	15,646	9,583
Total Current Liabilities	43,368	65,422	63,172	68,185	71,122	37,688
Long-Term Leases	284.32	349.62	532.34	490.11	577.85	1,017
Long-Term Deferred Tax Liabilities	30,779	31,178	30,351	28,187	7,770	-
Other Long-Term Liabilities	1,886	1,818	1,659	1,568	612.84	576.52
Total Liabilities	91,544	114,022	109,036	110,276	93,392	51,974
Common Stock	9,101	9,101	9,001	7,915	7,617	7,356
Additional Paid-In Capital	82,597	82,597	81,599	69,897	65,502	59,229
Retained Earnings	134,974	135,699	134,021	125,089	52,972	20,282
Treasury Stock	-587.16	-587.16	-587.16	-587.16	-587.16	-587.16
Comprehensive Income & Other	22,562	22,630	8,948	4,811	1,437	-2,754
Total Common Equity	248,646	249,439	232,982	207,125	126,940	83,526
Minority Interest	3.65	-11.16	-10.11	-9.07	-7.59	43.94
Shareholders' Equity	248,650	249,428	232,972	207,116	126,932	83,570
Total Liabilities & Equity	340,194	363,450	342,008	317,391	220,324	135,544
Total Debt	19,425	38,989	37,963	39,492	48,009	21,405
Net Cash (Debt)	-5,343	-540.17	-526.1	-19,606	-13,822	9,043
Net Cash Per Share	-250.84	-24.80	-25.30	-908.04	-743.19	602.01
Filing Date Shares Outstanding	18.16	18.16	17.96	15.79	15.19	14.67
Total Common Shares Outstanding	18.16	18.16	17.96	15.79	15.19	14.67
Working Capital	46,779	45,286	32,155	2,356	6,257	37,213
Book Value Per Share	13692.44	13736.10	12971.86	13118.31	8355.98	5693.27
Tangible Book Value	248,182	249,011	232,536	206,642	126,532	83,172
Tangible Book Value Per Share	13666.87	13712.53	12947.01	13087.76	8329.14	5669.13
Land	21,183	21,183	21,183	21,183	15,391	3,061
Buildings	12,383	12,383	12,383	12,383	9,790	7,251
Machinery	11,609	11,602	11,608	10,547	10,960	10,847

Source: S&P Global Market Intelligence. Standard template. Financial Sources.